Private: Fullwidth Portfolio Post

31

May2018

CADTH publishes CDR Update – Issue 136

2019 CDEC Meeting Schedule Released A new schedule format includes submission deadlines and guidance on when manufacturers can expect embargoed and final recommendations. Updated Advance Notification Form (effective immediately) New form includes an acknowledgement that information provided in the form may be shared with federal, provincial and territorial ... Read More

29

Mar2018

Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018

Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018 In January 2018, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) announced a five-year agreement that will reduce drug prices for all Canadians who use prescription generic drugs, participating public drug plans, and employee ... Read More

21

Mar2018

CADTH Invites Stakeholder Feedback on Proposed Revisions to the pCODR Clinician Engagement Process

Since launching a pilot project to expand clinician participation in the pan-Canadian Oncology Drug Review (pCODR) process in February 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) has received input from clinicians, the pCODR Expert Review Committee and the Provincial Advisory Group on ways to enhance ... Read More

09

Mar2018

CADTH Common Drug Review Releases New Update

On March 8, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 134). CADTH Common Drug Review Submissions May Be Filed up to 180 Days before Market Authorization In support of the Health Canada’s Regulatory Review of Drugs and Devices (R2D2) initiative and ... Read More

14

Feb2018

CADTH Common Drug Review Releases New Update

On February 13, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 133). Revisions to CADTH’s Biosimilar Review Process In August 2017, CADTH issued a consultation to seek input on how biosimilar reviews could be enhanced in Canada. Based on the ... Read More

21

Dec2017

CADTH Common Drug Review Releases New Update

On December 12, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 132). Update on Revised Process for Biosimilars In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the submission and review process for biosimilars through ... Read More

28

Nov2017

CADTH Common Drug Review Releases New Update

On November 27, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 131) Collaborative Workspaces: Revised Process for Filing CDR Submissions and Resubmissions The CADTH Common Drug Review (CDR) is aligning the process for secure file sharing with the ... Read More

16

Nov2017

CADTH Common Drug Review Releases New Update

On November 13, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 130). Revised Procedure for the CADTH Common Drug Review Resubmissions In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission requirements for its Common ... Read More

12

Oct2017

CADTH Common Drug Review Releases New Update

On October 11, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 129). Based on feedback from stakeholders, CADTH will be implementing the proposed revision to the resubmission eligibility criteria and a new randomized controlled trial will no longer be required ... Read More

29

Sep2017

CADTH Common Drug Review Releases New Update

On September 28, 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a new CDR Update (Issue 128) describing the following changes. Revised Procedure for Advance Notification of Pending CDR Submissions and Resubmissions CADTH has received numerous inquiries regarding challenges interpreting and complying with the ... Read More